Incorporation of Astragalus polysaccharides injection during concurrent chemoradiotherapy in advanced pharyngeal or laryngeal squamous cell carcinoma: preliminary experience of a phase II double-blind, randomized trial
ConclusionThis preliminary study demonstrated PG2 injection exhibited an excellent safety profile, and has potential in ameliorating the deterioration in QoL and the AEs associated with active anticancer treatment among patients with advanced pharyngeal or laryngeal HNSCC under CCRT. Further research in patients with other cancer types or treatment modalities may widen PG2 ’s application in clinical settings.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Astragalus | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Head and Neck Cancer | HNSCC | Laryngeal Cancer | Pain | Pharyngeal Cancer | Skin Cancer | Squamous Cell Carcinoma | Study